• Landa Shi, Yuqiang Wang, Longqing Li, Dean Chou, Yao Zhao, Shuhao Zhang, Limin Wang, Min Zhang, and Yilin Liu.
• Department of Orthopedic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
• Medicine (Baltimore). 2021 Sep 17; 100 (37): e27221.

BackgroundAnemia is one of the most common manifestations in patients with cancer. Recently, multiple studies have shown a positive correlation between pretreatment anemia and tumor prognosis. Yet, the relationship between pretreatment anemia and the prognosis of soft tissue sarcomas (STS) is unclear.MethodsWe searched the PubMed and EMBASE databases to identify relevant studies. Eligible studies were included according to the inclusion criteria to assess the relationship between pretreatment anemia and the prognosis of patients with STS. Prognostic significance was determined by studying hazard ratios (HR) and 95% confidence intervals (CIs).ResultsA total of 12 studies are included. If there is significant heterogeneity, a random-effects model is used. Pooled data indicated that pretreatment anemia is related to poor overall survival (HR = 2.13; 95%CI = 1.52-2.98), disease-specific survival (HR = 1.53; 95%CI = 1.20-1.96), and disease-free survival (HR = 1.55; 95%CI = 1.10-2.17). The results of the subgroup analysis also support this conclusion.ConclusionOur results suggest that pretreatment anemia may be a prognostic biomarker for STS.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

15 keywords...

hide…